Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

HIV London blood cancer transplant

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

seventure microbiome investment biotech

News and Trends 5 Mar 2019

Seventure Continues Microbiome Investment Success with Second Fund

After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […]

March 5, 2019 - 3 minutesmins - By Jonathan Smith

Horizon Europe Header

Best in Biotech 5 Mar 2019

5 Biotech Industry Challenges the EU’s Horizon Program Plans to Tackle

While the EU’s Horizon funding program is more often associated with academic research, a sizeable proportion of its funds are invested in the European biotech industry. With a new stage of the program being close to launch, I investigated some challenges for the industry that it hopes to solve. Beginning in 2021, Horizon Europe is […]

March 5, 2019 - 9 minutesmins - By David Cox

novago stroke ishemic regenerate 1

More News! 4 Mar 2019

Swiss Biotech Raises €8.8M to Progress Regenerative Stroke Treatment

The Swiss company NovaGo has raised €8.8M (CHF 10M) in Series A funding to develop one of the first therapies to help the nervous system regenerate after a stroke. Novago develops antibodies that inhibit Nogo-A, a key molecule that stops nerve cells from growing new connections in the adult brain and spinal cord. This lets […]

March 4, 2019 - 3 minutesmins - By Jonathan Smith

biogen nightstar therapeutics gene therapy ophthalmology

News and Trends 4 Mar 2019

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition of Nightstar bags it the UK company’s most advanced program. Currently in phase III, the therapy targets choroidemia, an incurable genetic condition which causes progressive […]

March 4, 2019 - 2 minutesmins - By Jonathan Smith

cureVac vaccine mRNA germany

News and Trends 1 Mar 2019

Rapid Response mRNA Vaccine Facility Gets €30M Funding

An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development grant to rapidly manufacture vaccines for regions hit by outbreaks of rabies, yellow fever and emerging diseases. CureVac is a company that develops vaccines made of mRNA, a molecule that lets cells translate genes into proteins. The company’s drug candidates […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

ADVERTISEMENT

Hansa Medical story Header 1

News and Trends 1 Mar 2019

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

aquaporin water purification membrane copenhagen skyline

Startup Scout 1 Mar 2019

This Biotech Uses Bacterial Proteins to Purify Water Faster

Aquaporin is a company named after a protein that transports water molecules across a cell membrane. With these water channels, the Danish biotech is able to purify water 50% faster than conventional technology. Mission: To use water channel proteins to purify water in applications such as cleaning drinking water, desalination and industrial wastewater treatment. As […]

March 1, 2019 - 4 minutesmins - By Jonathan Smith

hookipa cancer vaccine hiv cytomegalovirus

News and Trends 28 Feb 2019

Austrian Biotech Raises €33.2M to Fund Cancer Vaccines

A Series D round of €33.2M ($37.4M) is to help the biotech Hookipa advance the clinical development of therapeutic vaccines for virus-based cancers, as well as a prophylactic vaccine for cytomegalovirus, which can infect patients undergoing organ transplants. Currently at the preclinical stage, Hookipa’s therapeutic vaccines are designed to tackle cancers that are caused […]

February 28, 2019 - 2 minutesmins - By Jonathan Smith

Cell medica car t cancer therapy cover

News and Trends 27 Feb 2019

UK Biotech Gets Huge Grant to Launch Off-the-Shelf CAR-T Cancer Therapy to Clinic

The UK biotech Cell Medica has received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors. The funding will help the company to develop a special type of CAR-T cell therapy […]

February 27, 2019 - 3 minutesmins - By Jonathan Smith

Carbios recycling plant

More News! 27 Feb 2019

Carbios Creates First 100% Recycled Plastic Bottles With Enzymes

French biotech Carbios has managed to create plastic bottles from 100% recycled plastic using its specialized enzyme technology. The company’s recycling process focuses on plastic made from polyethylene terephthalate or PET, one of the most commonly used plastics. Importantly, it can be also be used to create customized bottles, a requirement for many brands. Carbios […]

February 27, 2019 - 2 minutesmins - By Helen Albert

cancer therapy tolremo

Interview 27 Feb 2019

How to Make Cancer Drug Resistance Futile

For many solid tumors, treatments undergo a cycle: the drugs initially work well, the tumor shrinks, but then becomes resistant again. Stefanie Flückiger-Mangual, CEO of the Swiss biotech Tolremo, believes that this cycle can be stopped. Solid tumors often act like a recurring villain in a TV series. Whatever drug you throw at them, however […]

February 27, 2019 - 5 minutesmins - By Jonathan Smith

ADVERTISEMENT